RxDoctor Payments Data

Anne Chang, MD

Dermatology · Stanford, CANPI 1013049188

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (58.6%), grants and travel and lodging — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Galderma Laboratories, L.p. at 39.8% of the total. Among dermatology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$106,441in general payments, 2019–2025

Across 107 payments — averaging $994.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galderma Laboratories, L.p.$42K
  • Regeneron$25K
  • Sun Pharmaceutical Industries Inc.$21K
  • Merck$10K
  • AbbVie$5K
  • Regeneron Healthcare Solutions, Inc.$3K
  • plus $38 from 2 others
$2,043,285in research payments, 2019–2025

Across 438 payments — averaging $4665.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$1.1M
  • Merck$967K
  • F. Hoffmann-la Roche AG$1K
  • Genentech, Inc.$753
  • Novartis$37

What the payments were for

  • Consulting fees$62,35059%
  • Speaking & faculty fees$4,0004%
  • Grants$25,49424%
  • Travel & lodging$12,17011%
  • Food & beverage$2,4122%
  • Education$150%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$106,441 in reported general payments places this provider in the 95th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$113,145
Medicare patients
224
Services billed
2,465

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab14$95,486
Dupixent SyringeDupilumab17$60,787
Fluorouracil32$3,416
Clindamycin Phosphate34$1,213
Metronidazole17$949
Fluocinonide21$899
Ketoconazole44$535
Triamcinolone Acetonide39$525
ValacyclovirValacyclovir Hcl14$480
Doxycycline Hyclate12$448
CiclopiroxCiclopirox Olamine12$383
Hydrocortisone20$82
Minoxidil11$79

Paid to pharmacies, not to this prescriber.

Other dermatology in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →